In this issue:
HCV-related mortality: familial factors
Consider %CD4 for HAART timing
Transmitted HIV-1 drug resistance decline
Adherence to HIV antiretroviral therapy
Atazanavir: better virological suppression
Dose intensity in HCV therapy
HIV transmission and superinfection
Clinical outcome of HIV-infected refugees
HIV transmission continues
Please login below to download this issue (PDF)